SEOM—GECOD clinical guideline for unknown primary cancer (2021)

被引：0

作者：

Ferrán Losa

Isaura Fernández

Olatz Etxaniz

Alejandra Giménez

Paula Gomila

Lara Iglesias

Federico Longo

Esteban Nogales

Antonio Sánchez

Gemma Soler

机构：

[1] Hospital de Sant Joan Despí Moisés Broggi-ICO Hospitalet,

[2] Hospital Álvaro Cunqueiro-IIGS,undefined

[3] Hospital Germans Trias I Pujol -ICO Badalona,undefined

[4] Hospital Lluís Alcanys de Xàtiva,undefined

[5] Hospital Miguel Servet (Zaragoza)/H,undefined

[6] Hospital Universitario 12 de Octubre,undefined

[7] Hospital Universitario Ramón y Cajal,undefined

[8] IRYCIS,undefined

[9] CIBERONC,undefined

[10] Hospital Universitario Virgen Macarena,undefined

[11] Hospital Universitario Puerta de Hierro Majadahonda,undefined

[12] Hospital Durán i Reynals-ICO Hospitalet,undefined

来源：

Clinical and Translational Oncology | 2022年 / 24卷

关键词：

Cancer; Unknown primary site; Diagnosis; Treatment;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Cancer of unknown primary site (CUP) is defined as a heterogeneous group of tumors that appear as metastases, and of which standard diagnostic work-up fails to identify the origin. It is considered a separate entity with a specific biology, and nowadays molecular characteristics and the determination of actionable mutations may be important in a significant group of patients. In this guide, we summarize the diagnostic, therapeutic, and possible new developments in molecular medicine that may help us in the management of this unique disease entity.

引用

页码：681 / 692

页数：11

共 311 条

[1]

Dykewicz CA(2001)Centers for Disease Control and Prevention (U.S.), infectious diseases society of America, American society of blood and marrow transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients Clin Infect Dis Off Publ Infect Dis Soc Am 33 139-144

[2]

Rassy E(2019)The currently declining incidence of cancer of unknown primary Cancer Epidemiol 61 139-141

[3]

Pavlidis N(2019)Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’ Br J Cancer 120 141-153

[4]

Conway A-M(2020)Exploring the biological hallmarks of cancer of unknown primary: where do we stand today? Br J Cancer 122 1124-1132

[5]

Mitchell C(2009)Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP Clin Transl Oncol 11 340-348

[6]

Kilgour E(2009)Treatment for patients with unknown primary cancer and favorable prognostic factors Semin Oncol 36 44-51

[7]

Brady G(2009)Development and validation of a bedside score to predict early death in cancer of unknown primary patients PLoS ONE 4 e6483-223

[8]

Dive C(2012)Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature Crit Rev Oncol Hematol 84 213-96

[9]

Cook N(2018)SEOM clinical guideline on unknown primary cancer (2017) Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 20 89-24

[10]

Rassy E(2011)Unknown primary tumors Biochim Biophys Acta 1816 13-304

← 1 2 3 4 5 6 7 8 9 10 →